T-cell

Estrella nears completion of SPAC listing

Estrella Immunopharma nears completion of SPAC listing

The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…
UPTD.US

Recent Articles

RELATED ARTICLES

  1. Lotus Technology nears end of SPAC listing
    Geely flexes deal-making muscle as Lotus Technology nears listing finish line
    LCAA.US
  2. ZG Group and Aquila aim to score Hong Kong’s first SPAC merger success
    7836.HK
  3. China-U.S. IPOs take big step toward resumption with Cheche listing
  4. Hong Kong’s first SPAC pumps up with steel trader ZG Group
    7836.HK
  5. New Horizon Health finds formula for profits ahead of schedule
    6606.HK
  6. Sinking Burning Rock faces de-listing. But could privatization bid come first?
    BNR.US
  7. Heated market for dueling blood cancer drugs lands BeiGene in court
    BGNE.US 6160.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners